Adient plc (ADNT), a global leader in automotive seating, carries a mostly bullish but notably split analyst view. This article reviews nine recent, attributable price targets rather than a single headline consensus figure. The current set ranges from $21 (Morgan Stanley and Stifel, both holding Buy or Equal Weight ratings) up to $29 (Citi and Wells Fargo). The arithmetic mean of these nine targets is about $24.89, rounded to a clean central target of $25.
Sentiment is tilted positive, with roughly seven Buy, Overweight, or Outperform ratings and two Equal Weight or Hold ratings. However, the direction of recent revisions has been downward. In October 2026, Stifel cut its target to $21 from $26, Barclays to $22 from $25, UBS to $23 from $29, and JPMorgan lowered its target to $25 while upgrading the shares to Overweight from Neutral. Earlier, Citi lowered its target to $29 from $33. The bullish camp generally emphasizes a margin-recovery and turnaround narrative, while the cautious camp focuses on slower earnings momentum and the risk that estimates still need to reset lower.
Adient closed near $17.60 on October 19, 2026, near the lower end of a 52-week range of roughly $16.51 to $27.32. Reaching the $25 central target would require an advance of about 42%, a large move. The stock trades at a price-to-sales ratio near 0.09 and a forward P/E (price-to-earnings) in the mid-single digits, and it sits below book value per share of roughly $22. These depressed multiples reflect a company generating substantial revenue but thin profitability, with trailing twelve-month revenue near $15 billion and net income of only about $48 million.
The potential path toward the target would likely depend on the company's multiyear effort to reset unfavorable legacy contracts and expand margins, rather than on revenue growth alone. Analysts such as Deutsche Bank have framed the stock around a "compelling turnaround story," citing an inflecting China business and benefits from automakers onshoring production in the U.S. For the target to become credible, the market would need to see sustained improvement in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margins and fewer downward estimate revisions.
Adient's shares have been in a downtrend, down roughly 23% over the past 52 weeks. The stock sits below both its 50-day and 200-day moving averages, near roughly $18.40 and $20.70 respectively. The 52-week low near $16.51 (set in early October 2026) is the primary support level to watch, while the 200-day average around $20.70 and the prior 52-week high near $27.32 represent key resistance zones. A durable move toward $25 would likely first require reclaiming the $20–$21 area, which has acted as resistance.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may apply different assumptions. The next confirmed catalyst is Adient's fiscal fourth-quarter and full-year results, scheduled for November 4, 2026, which should clarify guidance and the pace of margin recovery. Investors should also monitor analyst revisions, automotive production data, China business trends, commodity and freight costs, and any trade-policy developments. None of these can guarantee the path of the share price, but they are the signals most likely to shift expectations.
For traders looking to monitor changing conditions in real time, AI Daily Buy/Sell Signals offers a data-driven way to track shifting technical and market behavior across thousands of stocks and ETFs. The platform uses artificial intelligence to continuously analyze price action and generate Buy, Sell, or Hold signals as conditions evolve, helping users spot opportunities, manage existing positions, and identify emerging trends more efficiently. As Adient's price navigates its recent range, such tools can complement fundamental research by flagging changes in momentum that manual review might miss.
The $25 central target for Adient is an average of nine verified analyst price targets spanning $21 to $29, and it sits roughly 42% above the latest price near $17.60. Support for the target rests on a credible margin-recovery and turnaround thesis, a very low valuation, and several recent upgrades. The principal obstacles are persistent negative estimate revisions, thin profitability, and a cyclical, macro-sensitive industry backdrop. The wide gap between the lowest and highest targets shows that even professional forecasts disagree sharply about the pace of recovery. Whether Adient can reach $25 ultimately depends on whether its earnings revisions stabilize and margins improve, which upcoming quarterly results and guidance will help clarify.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ADNT has been closely correlated with LEA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if ADNT jumps, then LEA could also see price increases.
| Ticker / NAME | Correlation To ADNT | 1D Price Change % | ||
|---|---|---|---|---|
| ADNT | 100% | +1.60% | ||
| LEA - ADNT | 69% Closely correlated | +1.65% | ||
| MGA - ADNT | 56% Loosely correlated | +4.22% | ||
| DCH - ADNT | 53% Loosely correlated | +5.74% | ||
| VC - ADNT | 50% Loosely correlated | +7.66% | ||
| CPS - ADNT | 46% Loosely correlated | +7.30% | ||
More | ||||
| Ticker / NAME | Correlation To ADNT | 1D Price Change % |
|---|---|---|
| ADNT | 100% | +1.60% |
| ADNT (2 stocks) | 79% Closely correlated | +1.62% |
| Producer Manufacturing (348 stocks) | 5% Poorly correlated | -0.44% |